[Three cases of fatal thrombocytopenia after oxaliplatin-based chemotherapy]

Gan To Kagaku Ryoho. 2013 Nov;40(11):1557-60.
[Article in Japanese]

Abstract

Oxaliplatin is a platinum salt that is particularly effective for treating gastrointestinal tumors. However, some reports state that oxaliplatin-based chemotherapy triggers fatal thrombocytopenia. Myelosuppression is recognized as the main cause of oxaliplatin-related thrombocytopenia, and other mechanisms for this side effect have been suggested, including splenic sequestration of platelets related to oxaliplatin-induced liver damage and immune thrombocytopenia. Other causes of thrombocytopenia such as thrombotic thrombocytopenic purpura, immune thrombocytopenic purpura, heparin-induced thrombocytopenia, and pseudothrombocytopenia should also be considered. We encountered 3 patients who developed fatal thrombocytopenia after oxaliplatin-based chemotherapy and describe the differential diagnosis of fatal thrombocytopenia here.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Colonic Neoplasms / drug therapy*
  • Female
  • Humans
  • Middle Aged
  • Organoplatinum Compounds / adverse effects*
  • Organoplatinum Compounds / therapeutic use
  • Oxaliplatin
  • Thrombocytopenia / chemically induced*

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Oxaliplatin